Recent discussions among oncologists in West Virginia highlighted the challenges hindering the widespread use of Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma. Despite the therapy’s availability, social and logistical barriers prevent many eligible patients from accessing this innovative treatment option. Dr. Konstantinos Sdrimas, an expert in medical oncology, emphasized the importance of addressing these barriers to improve patient outcomes. Advancements in manufacturing processes and reduced hospitalization times are making CAR T-cell therapy more attractive to patients, paving the way for broader adoption in the field of oncology.
Read more about this — here
